Literature DB >> 11653056

Community-equipoise and the ethics of randomized clinical trials.

Fred Gifford.   

Abstract

This paper critically examines a particular strategy for resolving the central ethical dilemma associated with randomized clincial trials (RCTs) -- the "community equipoise" strategy (CE). The dilemma is that RCTs appear to violate a physician's duty to choose that therapy which there is most reason to believe is in the patient's best interest, randomizing patients even once evidence begins to favor one treatment. The community equipose strategy involves the suggestion that our judgment that neither treatment is to be preferred (that there obtains a state of "equipoise") is to be assessed according to a community rather than an individual standard. Thus, though a physician may personally believe that there is some reason to prefer one treatment, patients can legitimately be randomized if there remains disagreement in the community of medical professionals. Rationales in favor of this conception include the following: (i) medical knowledge is best understood as residing in the community, (ii) the judgments of others count as evidence, and so should change one's own opinion, (iii) subjects would not be better off outside the trial, and (iv) the point of any trial is the resolution of dispute in the medical community. I critically examine these rationales and argue that they are insufficient. Amongst the problems are tensions between various of these underlying rationales, and important ambiguities in just what the CE criterion is to amount to. Finally, I argue that even if use of CE was justified, it would not justify carrying out RCTs anywhere near long enough to discharge our duty to gain reliable knowledge on which to base safe and effective medical practice. Hence, we need some different justification for carrying out RCTs.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research

Mesh:

Year:  1995        PMID: 11653056     DOI: 10.1111/j.1467-8519.1995.tb00306.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  18 in total

1.  Uncertainty about clinical equipoise. Clinical equipoise and the uncertainty principles both require further scrutiny.

Authors:  F Gifford
Journal:  BMJ       Date:  2001-03-31

Review 2.  Equipoise: asking the right questions for clinical trial design.

Authors:  Steven Joffe; Franklin G Miller
Journal:  Nat Rev Clin Oncol       Date:  2012-01-10       Impact factor: 66.675

Review 3.  Should desperate volunteers be included in randomised controlled trials?

Authors:  P Allmark; S Mason
Journal:  J Med Ethics       Date:  2006-09       Impact factor: 2.903

4.  Uncertainty and the ethics of clinical trials.

Authors:  Sven Ove Hansson
Journal:  Theor Med Bioeth       Date:  2006

5.  Ethical Considerations in Ending Exploratory Brain-Computer Interface Research Studies in Locked-in Syndrome.

Authors:  Eran Klein; Betts Peters; Matt Higger
Journal:  Camb Q Healthc Ethics       Date:  2018-10       Impact factor: 1.284

6.  A public health perspective on research ethics.

Authors:  D R Buchanan; F G Miller
Journal:  J Med Ethics       Date:  2006-12       Impact factor: 2.903

7.  Unruptured Intracranial Aneurysms. Opinions of Experts in Endovascular Treatment Are Coherent,Weighted in Favour of Treatment, and Incompatible with ISUIA.

Authors:  J Raymond; T Nguyen; M Chagnon; G Gevry
Journal:  Interv Neuroradiol       Date:  2007-09-15       Impact factor: 1.610

8.  Competing commitments in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Steven Joffe; Karen Albert; Jill Rosenbaum; Lorna Simon
Journal:  IRB       Date:  2009 Sep-Oct

9.  Participation of pharmacists in clinical trial recruitment for low back pain.

Authors:  Christina Abdel Shaheed; Christopher G Maher; Kylie A Williams; Andrew J McLachlan
Journal:  Int J Clin Pharm       Date:  2014-08-08

Review 10.  The clinical investigator-subject relationship: a contextual approach.

Authors:  David B Resnik
Journal:  Philos Ethics Humanit Med       Date:  2009-12-03       Impact factor: 2.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.